GO:1901211 negative regulation of cardiac chamber formation: Developmental Checkpoint, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901211 (negative regulation of cardiac chamber formation) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of cardiac chamber formation.
• Cardiac chamber formation is a tightly orchestrated developmental program; its negative regulation ensures correct chamber number, size, and alignment, and prevents premature or ectopic chamber differentiation.
• Key molecular players include developmental signaling pathways such as Wnt/β-catenin, Notch, and retinoic acid, which act as brakes on chamber specification and growth.
• Dysregulation of negative regulatory checkpoints is linked to congenital heart defects such as chamber hypoplasia, septal defects, and abnormal chamber patterning.
• Experimental models for studying this process include zebrafish, mouse, and human induced pluripotent stem cell (hiPSC)-derived cardiac organoids, combined with CRISPR-based genome editing.
• CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect causal roles of candidate genes in negative regulation of cardiac chamber formation.
Description
Cardiac chamber formation is a fundamental step in heart development, during which the primitive heart tube undergoes looping, ballooning, and septation to produce distinct atrial and ventricular chambers. This process must be precisely controlled in time and space; excessive or premature chamber formation can lead to structural malformations, while insufficient chamber formation results in hypoplastic hearts. The Gene Ontology term GO:1901211, negative regulation of cardiac chamber formation, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of cardiac chamber formation. Understanding this term is essential for developmental biologists, cardiologists, and regenerative medicine researchers because it defines the molecular brakes that safeguard normal heart morphogenesis. At the molecular level, negative regulation of cardiac chamber formation is mediated by signaling pathways and transcription factors that restrict chamber-specific gene expression programs. For example, Wnt/β-catenin signaling has been shown to regulate endocardial cushion growth by suppressing p21, a process that influences chamber morphogenesis. In zebrafish, deletion of Pr72 causes cardiac developmental defects, highlighting the importance of specific gene products in chamber formation and its regulation. These findings illustrate that negative regulation is not a passive default but an active, genetically encoded program. For researchers, GO:1901211 provides a standardized framework to annotate and compare gene functions across species. It enables functional enrichment analysis of transcriptomic and proteomic datasets from developing hearts, and it helps prioritize candidate genes for functional validation using CRISPR-based models. As the field moves toward precision models of congenital heart disease, the ability to manipulate negative regulatory checkpoints will be critical for understanding disease mechanisms and developing therapeutic strategies.
negative regulation of cardiac chamber formation At A Glance
| GO ID | GO:1901211 |
|---|---|
| GO term | negative regulation of cardiac chamber formation |
| Ontology | biological_process |
| Synonym | down regulation of cardiac chamber formation; down-regulation of cardiac chamber formation; downregulation of cardiac chamber formation; down regulation of heart chamber formation; down-regulation of heart chamber formation; downregulation of heart chamber formation; inhibition of cardiac chamber formation; inhibition of heart chamber formation; negative regulation of heart chamber formation |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of cardiac chamber formation during heart development. |
| Related process | Cardiac chamber formation (GO:0003205) and its positive regulation. |
| Taxonomic scope | Metazoa, particularly vertebrates with chambered hearts. |
| Cellular context | Cardiac progenitor cells, cardiomyocytes, endocardial and epicardial cells. |
| Disease relevance | Congenital heart defects, chamber hypoplasia, septal defects, and abnormal chamber patterning. |
What Is GO:1901211?
GO:1901211, negative regulation of cardiac chamber formation, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cardiac chamber formation. In other words, it encompasses molecular and cellular events that act as brakes on the developmental program responsible for building the heart's chambers. This includes inhibition of chamber-specific gene expression, restriction of progenitor proliferation or differentiation, and modulation of signaling pathways that promote chamber morphogenesis. The term is a biological process annotation and is distinct from positive regulation or the chamber formation process itself.
Why Is negative regulation of cardiac chamber formation Important in Cell Biology?
GO:1901211 is important because it defines the regulatory mechanisms that prevent excessive or ectopic cardiac chamber formation, thereby ensuring a correctly patterned heart. Disruption of these negative regulatory checkpoints can lead to congenital heart defects, including hypoplastic chambers, septal abnormalities, and misalignment of the outflow tract. Understanding this term helps researchers interpret developmental signaling networks, identify disease-causing variants, and design targeted interventions in regenerative cardiology.
• Provides a standardized annotation for genes that restrict cardiac chamber formation, enabling cross-species comparisons.
• Helps explain how signaling pathways such as Wnt/β-catenin and Notch act as developmental brakes.
• Links developmental biology to congenital heart disease by highlighting checkpoints whose failure causes malformations.
• Supports functional enrichment analysis of omics data from developing hearts.
• Guides CRISPR-based validation of candidate genes in zebrafish, mouse, and hiPSC models.
• Informs regenerative strategies by revealing barriers to controlled cardiomyocyte differentiation.
• Facilitates drug discovery by identifying pathways that can be modulated to prevent chamber defects.
• Enhances understanding of evolutionary differences in heart chamber number and size.
What Happens During negative regulation of cardiac chamber formation?
Initiation of negative regulatory signals
In simple terms: The heart starts to form chambers, but certain signals tell it to slow down or stop.
Negative regulation of cardiac chamber formation begins when extracellular or intracellular signals activate pathways that oppose chamber specification. For example, Wnt/β-catenin signaling can suppress p21 to regulate endocardial cushion growth, a process that influences chamber morphogenesis. In zebrafish, deletion of Pr72 causes cardiac developmental defects, indicating that specific gene products are required to modulate chamber formation. These signals often originate from surrounding tissues such as the endocardium, epicardium, or neural crest, and they converge on transcription factors that repress chamber-specific gene programs.
Transcriptional repression of chamber-specific genes
In simple terms: Master switches for chamber identity are turned off or kept off.
Once negative regulatory signals are received, transcription factors and chromatin-modifying complexes repress genes that drive chamber formation. This includes inhibition of chamber-specific myosin isoforms, natriuretic peptides, and transcription factors such as Nkx2-5, Tbx5, and Gata4 when their activity must be restrained. The repression is context-dependent; for instance, β-catenin regulates endocardial cushion growth by suppressing p21, which in turn affects cell cycle progression and chamber morphogenesis. This transcriptional brake ensures that chambers form only at the correct time and place.
Modulation of progenitor proliferation and differentiation
In simple terms: The pool of heart-building cells is kept from expanding or specializing too quickly.
Negative regulation also operates at the level of cardiac progenitor cells. Signaling pathways such as Notch and retinoic acid can limit the proliferation and differentiation of second heart field progenitors, thereby restricting the number of cells available for chamber formation. In zebrafish, loss of Pr72 leads to cardiac developmental defects, suggesting that Pr72 normally participates in restraining progenitor expansion or promoting correct differentiation timing. Similarly, microRNA-21 up-regulation promotes migration and proliferation of Sca-1+ cardiac stem cells in mice, indicating that miRNA networks can modulate progenitor behavior relevant to chamber formation.
Integration with hemodynamic and metabolic cues
In simple terms: Blood flow and energy status help fine-tune chamber growth.
As the heart begins to beat and pump blood, hemodynamic forces and metabolic signals provide feedback that can negatively regulate chamber formation. For example, cardiac chamber volume is related to baroreflex activity in normal humans, highlighting the interplay between chamber geometry and physiological control. Metabolic regulators such as PKM2 are key regulators of cardiac lipid metabolism in mice, and altered metabolism can influence developmental decisions. Additionally, endothelial nitric oxide synthase (eNOS) signaling, studied in platelet subpopulations, illustrates how nitric oxide pathways can modulate cardiovascular cell behavior, with potential relevance to chamber morphogenesis. These cues help match chamber size and function to the organism's physiological demands.
Resolution and stabilization of chamber identity
In simple terms: Once the right number and size of chambers are made, the brakes are adjusted to maintain the result.
After negative regulation has restricted chamber formation to the appropriate extent, stabilizing mechanisms maintain chamber identity and prevent ectopic chamber formation. This involves epigenetic modifications, feedback loops, and structural remodeling of the extracellular matrix. Disruption of these stabilization processes can lead to congenital heart defects, as seen in zebrafish models with cardiac developmental defects. The balance between positive and negative regulation ultimately determines the final architecture of the heart, and its perturbation is a major cause of chamber malformations.
Key Genes Involved in GO:1901211 negative regulation of cardiac chamber formation
The following genes and proteins have been implicated in negative regulation of cardiac chamber formation or in related cardiac developmental processes, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTNNB1 (β-catenin) | Regulates endocardial cushion growth by suppressing p21; modulates chamber morphogenesis | Key node in Wnt signaling; target for CRISPR knockout and point mutation studies in cardiac development |
| CDKN1A (p21) | Cell cycle inhibitor suppressed by β-catenin; influences cushion growth and chamber formation | Downstream effector; useful for overexpression and knockout models to dissect proliferation control |
| PR72 (PPP2R3A) | Zebrafish deletion causes cardiac developmental defects; likely involved in chamber formation regulation | Model for loss-of-function studies in zebrafish; candidate for knock-in of patient variants |
| MIR21 (miR-21) | Promotes migration and proliferation of Sca-1+ cardiac stem cells in mice | Potential modulator of progenitor behavior; overexpression and knockout models in mice |
| PKM2 | Key regulator of cardiac lipid metabolism in mice | Metabolic link to chamber formation; conditional knockout and overexpression models |
| EPAS1 (HIF-2α) | Attenuates atherosclerosis initiation at disturbed flow sites through endothelial fatty acid uptake | Endothelial signaling; may influence chamber development via vascular cues |
| NOS3 (eNOS) | Differential eNOS signaling regulates platelet adhesion and aggregation | Nitric oxide pathway; potential role in cardiovascular development and chamber morphogenesis |
| MAO-A | Monoamine oxidase expression in atria; decreased by empagliflozin/dapagliflozin in cardiac patients | Atrial biology; may affect chamber-specific gene expression |
| NPPA | Atrial natriuretic peptide; chamber-specific marker | Readout for chamber identity in knockout and overexpression studies |
| NPPB | Brain natriuretic peptide; chamber-specific marker | Readout for ventricular identity and stress |
| MYH6 | Atrial myosin heavy chain; chamber-specific | Marker for atrial chamber formation |
| MYH7 | Ventricular myosin heavy chain; chamber-specific | Marker for ventricular chamber formation |
| TBX5 | Transcription factor essential for chamber specification | Target for CRISPR editing to study chamber identity |
| NKX2-5 | Early cardiac transcription factor | Master regulator; knockout models show chamber defects |
| GATA4 | Cardiac transcription factor | Dosage-sensitive regulator of chamber formation |
| HAND1 | Ventricular transcription factor | Marker and regulator of ventricular chamber formation |
| HAND2 | Right ventricular and outflow tract transcription factor | Regulator of chamber morphogenesis |
| MEF2C | Cardiac transcription factor | Downstream effector of chamber gene programs |
How Is negative regulation of cardiac chamber formation Regulated?
Negative regulation of cardiac chamber formation is itself regulated by multiple upstream inputs. Wnt/β-catenin signaling acts as a context-dependent brake; β-catenin regulates endocardial cushion growth by suppressing p21, thereby influencing chamber morphogenesis. Notch signaling, retinoic acid gradients, and BMP/TGF-β pathways also modulate chamber formation by restricting progenitor differentiation. Metabolic cues, such as PKM2-mediated lipid metabolism, can influence cardiac development. Additionally, microRNAs such as miR-21 regulate cardiac stem cell proliferation and migration, providing another layer of post-transcriptional control. Hemodynamic forces and baroreflex activity are correlated with chamber volume, suggesting physiological feedback. Finally, endothelial nitric oxide signaling may modulate cardiovascular cell behavior relevant to chamber formation.
negative regulation of cardiac chamber formation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PR72 (PPP2R3A) | Cardiac developmental defects in zebrafish | Zebrafish knockout and knock-in models |
| CTNNB1 (β-catenin) | Endocardial cushion defects and chamber malformations | Mouse conditional knockout and point mutation models |
| PKM2 | Cardiac lipid metabolism and metabolic heart disease | Mouse conditional knockout and overexpression |
| EPAS1 (HIF-2α) | Atherosclerosis and endothelial dysfunction | Mouse endothelial-specific knockout |
| MIR21 (miR-21) | Cardiac stem cell proliferation and migration | Mouse overexpression and knockout models |
Congenital heart defects and chamber hypoplasia
Disruption of negative regulatory checkpoints can cause congenital heart defects, including hypoplastic chambers and septal abnormalities. In zebrafish, deletion of Pr72 causes cardiac developmental defects, demonstrating that loss of specific gene products leads to malformed hearts. Similarly, dysregulated β-catenin signaling affects endocardial cushion growth and chamber morphogenesis, contributing to structural heart disease. These findings underscore the clinical importance of understanding GO:1901211 in the context of pediatric cardiology.
Atrial and ventricular arrhythmias
Chamber-specific gene expression and geometry influence electrophysiological properties. Atrial monoamine oxidase expression, which can be modulated by empagliflozin and dapagliflozin, is linked to oxidative stress in cardiac patients. Abnormal chamber formation may predispose to arrhythmias by altering conduction pathways and chamber size. Although direct evidence for GO:1901211 in arrhythmia is limited, the interplay between chamber morphology and electrical function is well recognized.
Metabolic and ischemic heart disease
Metabolic regulators such as PKM2 influence cardiac lipid metabolism and may affect developmental and pathological chamber remodeling. EPAS1 attenuates atherosclerosis initiation at disturbed flow sites, linking endothelial signaling to cardiovascular disease. These pathways may intersect with negative regulation of chamber formation, particularly in conditions where metabolic stress alters cardiac development or repair.
From negative regulation of cardiac chamber formation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene cause ectopic or excessive chamber formation? | CRISPR knockout in zebrafish or mouse |
| Does a patient variant impair negative regulation of chamber formation? | CRISPR point mutation knock-in in hiPSCs or zebrafish |
| Does overexpression of a repressor reduce chamber size? | CRISPR-mediated overexpression (e.g., safe-harbor knock-in) in mouse or hiPSC-derived cardiomyocytes |
| Where and when is a candidate protein expressed during chamber formation? | Tagged knock-in (e.g., GFP) in mouse or zebrafish |
| What transcriptional networks are altered upon loss of a negative regulator? | RNA-seq and ATAC-seq in knockout vs. wild-type embryos |
| Can a small molecule modulate negative regulation to prevent chamber defects? | hiPSC-derived cardiac organoids and drug screening |
How to Study the negative regulation of cardiac chamber formation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify chamber-specific signatures in knockout models |
| ATAC-seq | Chromatin accessibility | Map regulatory elements controlling chamber genes |
| ChIP-seq | Transcription factor binding sites | Determine β-catenin and p21 targets in cushion cells |
| Proteomics | Protein abundance and modifications | Profile metabolic enzymes like PKM2 in heart tissue |
| Phosphoproteomics | Signaling pathway activity | Analyze eNOS and Wnt pathway dynamics |
| Light-sheet microscopy | 3D morphology of developing heart | Visualize chamber formation in zebrafish |
| Lineage tracing | Progenitor cell fate | Track cardiac progenitor contributions to chambers |
| Cardiac organoids | Human-relevant chamber-like structures | Model congenital heart defects and drug responses |
Transcriptomic profiling (RNA-seq)
RNA sequencing of developing hearts or hiPSC-derived cardiomyocytes can identify genes and pathways whose expression changes when negative regulators are perturbed. For example, comparing wild-type and Pr72-deficient zebrafish may reveal chamber-specific gene signatures. This approach helps annotate GO:1901211 by linking candidate genes to chamber formation programs.
Epigenomic mapping (ATAC-seq, ChIP-seq)
Assay for Transposase-Accessible Chromatin (ATAC-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) can identify regulatory elements and transcription factor binding sites that control chamber-specific gene expression. Such methods can reveal how β-catenin and p21 interact at the chromatin level to regulate cushion growth. These techniques are essential for understanding the transcriptional brakes in GO:1901211.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify protein abundance and post-translational modifications in cardiac tissues. For instance, PKM2 and its metabolic targets can be profiled in mouse hearts to understand metabolic regulation of chamber formation. Phosphoproteomics can uncover signaling events downstream of eNOS or β-catenin.
Imaging and lineage tracing
Confocal and light-sheet microscopy of fluorescently labeled hearts in zebrafish or mouse embryos allows real-time visualization of chamber morphogenesis. Lineage tracing using Cre-lox or CRISPR-based reporters can determine the fate of progenitor cells when negative regulators are lost. These imaging approaches provide spatial and temporal resolution of GO:1901211.
How CRISPR Can Be Used to Study GO:1901211 negative regulation of cardiac chamber formation
Knockout
CRISPR knockout of candidate genes such as PR72 or CTNNB1 in zebrafish or mouse models can reveal their requirement for negative regulation of cardiac chamber formation. For example, Pr72 deletion in zebrafish causes cardiac developmental defects, validating its role in chamber formation. Knockout studies help establish causality and identify downstream effectors.
Point Mutation
CRISPR point mutation knock-in can model patient-specific variants in genes like CTNNB1 or PR72. This approach allows researchers to test whether a single amino acid change alters the protein's ability to restrain chamber formation, providing mechanistic insight into congenital heart defects.
Knock-in
Tagged knock-in (e.g., GFP or HA) of genes involved in negative regulation enables visualization and biochemical isolation of the protein in developing hearts. This is useful for determining expression patterns and interaction partners of proteins such as β-catenin or Pr72 during chamber formation.
Overexpression
CRISPR-mediated overexpression of a negative regulator (e.g., via safe-harbor locus insertion) can test whether increased dosage reduces chamber size or prevents ectopic chamber formation. Overexpression of miR-21, for instance, promotes cardiac stem cell proliferation and migration, which may influence chamber formation. Such models are valuable for gain-of-function studies.
How EDITGENE Supports negative regulation of cardiac chamber formation Research
Researchers studying negative regulation of cardiac chamber formation-related genes often need to determine whether a candidate gene is causally involved in restricting chamber formation, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point mutation models to knock-in reporters, overexpression systems, and high-throughput library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cardiac chamber formation research.
Frequently Asked Questions About negative regulation of cardiac chamber formation
What is GO:1901211 negative regulation of cardiac chamber formation?
GO:1901211 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cardiac chamber formation. It encompasses molecular brakes that ensure correct heart chamber development.
What genes are involved in negative regulation of cardiac chamber formation?
Genes such as CTNNB1 (β-catenin), CDKN1A (p21), PR72 (PPP2R3A), MIR21, and PKM2 have been implicated in processes that modulate cardiac chamber formation.
How is cardiac chamber formation negatively regulated during development?
Negative regulation occurs through signaling pathways like Wnt/β-catenin, Notch, and retinoic acid, which repress chamber-specific gene programs and restrict progenitor proliferation and differentiation.
What diseases are associated with defective negative regulation of cardiac chamber formation?
Disruption of these checkpoints can lead to congenital heart defects, including chamber hypoplasia, septal defects, and abnormal chamber patterning.
Which model organisms are used to study negative regulation of cardiac chamber formation?
Zebrafish and mouse are commonly used, along with hiPSC-derived cardiac organoids, because they allow genetic manipulation and real-time imaging of heart development.
How can CRISPR be used to study negative regulation of cardiac chamber formation?
CRISPR knockout, point mutation knock-in, tagged knock-in, and overexpression models enable researchers to test the causal role of specific genes in restricting chamber formation.
What is the role of β-catenin in cardiac chamber formation?
β-catenin regulates endocardial cushion growth by suppressing p21, thereby influencing chamber morphogenesis and contributing to negative regulation of chamber formation.
What is the role of Pr72 in heart development?
Deletion of Pr72 in zebrafish causes cardiac developmental defects, indicating that Pr72 is required for normal heart development, potentially through negative regulation of chamber formation.
How does miR-21 affect cardiac stem cells?
Up-regulation of miR-21 promotes migration and proliferation of Sca-1+ cardiac stem cells in mice, which may influence chamber formation and repair.
What methods are used to study negative regulation of cardiac chamber formation?
Common methods include RNA-seq, ATAC-seq, ChIP-seq, proteomics, light-sheet microscopy, lineage tracing, and CRISPR-based genome editing in zebrafish, mouse, and hiPSC models.
Conclusion
GO:1901211, negative regulation of cardiac chamber formation, defines the essential biological brakes that ensure proper heart chamber development. Research using zebrafish, mouse, and hiPSC models has begun to uncover the signaling pathways and genes, such as β-catenin, p21, and Pr72, that mediate this regulation. Understanding these mechanisms is critical for diagnosing and potentially treating congenital heart defects and for advancing regenerative cardiology. As CRISPR technologies mature, the ability to precisely manipulate candidate genes will accelerate the functional annotation of GO:1901211 and reveal new therapeutic targets. EDITGENE's comprehensive CRISPR services, from knockout to library screening, provide researchers with the tools needed to dissect these pathways and translate discoveries into clinical benefit.
References
- 1. Ionică LN et al.. 2025. Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients.. Mol Cell Biochem 480(3):1645-1655 PMID: 39042348
- 2. Pirri D et al.. 2024. EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake.. Circ Res 135(8):822-837 PMID: 39234692
- 3. Zhou Q et al.. 2016. Up-Regulation of miRNA-21 Expression Promotes Migration and Proliferation of Sca-1+ Cardiac Stem Cells in Mice.. Med Sci Monit 22:1724-32 PMID: 27210794
- 4. Lee KCY et al.. 2025. PKM2 is a key regulator of cardiac lipid metabolism in mice.. Mitochondrion 85:102070 PMID: 40706825
- 5. Liu H et al.. 2023. β-Catenin regulates endocardial cushion growth by suppressing p21.. Life Sci Alliance 6(9) PMID: 37385754
- 6. Nabel EG et al.. 1987. Relationship of cardiac chamber volume to baroreflex activity in normal humans.. J Clin Endocrinol Metab 65(3):475-81 PMID: 3624410
- 7. Song G et al.. 2018. Deletion of Pr72 causes cardiac developmental defects in Zebrafish.. PLoS One 13(11):e0206883 PMID: 30481179
- 8. Radziwon-Balicka A et al.. 2017. Differential eNOS-signalling by platelet subpopulations regulates adhesion and aggregation.. Cardiovasc Res 113(14):1719-1731 PMID: 29016749
